Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT06210360 Not yet recruiting - Pancreatic Cancer Clinical Trials

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

This multicentric randomized trial will compare the efficacy and safety of neoadjuvant chemotherapy + surgery + adjuvant chemotherapy or surgery + adjuvant chemotherapy in patients with high-risk resectable pancreatic cancer. NALIRIFOX (5-fluorouracil, leucovorin, irinotecan liposome injection and oxaliplatin) will be used as the chemotherapy regimen.

NCT ID: NCT06205849 Not yet recruiting - Pancreatic Cancer Clinical Trials

Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

This is a phase I study of an agonistic CD40 antibody (mitazalimab) injected intratumorally at the time of surgical IRE in patients with locally advanced pancreatic cancer. Intratumoral delivery has potential to be more effective than systemic (intravenous) delivery while decreasing the systemic side effects of immunotherapy. We hypothesize that local delivery of mitazalimab at the time of IRE in patients with locally advanced pancreatic cancer will be safe, augment the immune effects of IRE, and decrease the risk of recurrence.

NCT ID: NCT06203821 Not yet recruiting - Pancreatic Cancer Clinical Trials

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..

NCT ID: NCT06196671 Not yet recruiting - Pancreatic Cancer Clinical Trials

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

PTCA199-8
Start date: December 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of oncolytic virus plus PD-1 inhibitor to Patients with Advanced Pancreatic Cancer.

NCT ID: NCT06196658 Not yet recruiting - Pancreatic Cancer Clinical Trials

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Start date: January 1, 2024
Phase: Early Phase 1
Study type: Interventional

This is a early Phase 1 open-label study to explore the safety and possible efficacy of EX02 CAR T cell therapy in the treatment of patients with unresectable and/or metastatic pancreatic/bile duct cancer. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy of cyclophosphamide and fludarabine, and an intra-tumoral injection or intraperitoneal infusion of Ex02 CAR T cells, probably followed by an intravenous infusion of EX02 CAR T cells. Each participant will proceed through the following study procedures: - Screening - Enrollment/Leukapheresis - Conditioning chemotherapy - CAR T treatment - Post-treatment assessment - Long-term follow-up

NCT ID: NCT06166147 Not yet recruiting - Pancreatic Cancer Clinical Trials

A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection

Start date: December 22, 2023
Phase:
Study type: Observational

This study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from clinically-annotated individuals.

NCT ID: NCT06156267 Not yet recruiting - Pancreatic Cancer Clinical Trials

Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

Start date: January 2024
Phase: Early Phase 1
Study type: Interventional

This is a phase 1, open-label study to evaluate the safety and tolerability of neoantigen personalized mRNA tumour vaccine combined with Adebrelimab (a PD-L1 humanized monoclonal antibody) in patients with surgically resected pancreatic adenocarcinoma.

NCT ID: NCT06153368 Not yet recruiting - Pancreatic Cancer Clinical Trials

Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC

Start date: December 19, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, single arm, single center, phase II study of cadonilimab plus mFOLFIRINOX as conversion therapy in patients with locally advanced pancreatic cancer.

NCT ID: NCT06134960 Not yet recruiting - Pancreatic Cancer Clinical Trials

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

Start date: November 16, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.

NCT ID: NCT06134765 Not yet recruiting - Colorectal Cancer Clinical Trials

Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

A multi-cohort, open-label, multicenter exploratory clinical study of Bemalenograstim alfa for the prevention of reduced absolute neutrophil count(ANC) in patients with colorectal cancer/pancreatic cancer following a bi-weekly chemotherapy regimen.A total of 89 patients are planned to be enrolled.